Antithrombotic agents
Antithrombotic agents has been studied in 12 papers since 2022: 11 observational studies in people, 1 review; 5 in the past year. The newest paper, Jul 25, 2026: “Vascular risk factors after stroke in the older people: a population-based study”.
12 papers study it14 findingsUpdated
1 new paper in 30 daysSee all 12 papers on antithrombotic agents
At a glance
The findings reach people, from one lab or study. 9 independent labs in 7 countries.
“antithrombotic (HR 1.145, p = 0.042) medication”
1 of its findings points the other way.
- 9 independent labs in 7 countries
- 1 finding against
- Funders: Aarne Koskelo Foundation and others
- Humans11
What did studies of antithrombotic agents find?
6Studies of antithrombotic agents measured 6 outcomes, among them cerebral microbleeds, intracranial hemorrhage and poor functional outcome.
Cerebral microbleeds
no changein humans2OR 1.16
2 studies
Cerebral microbleeds
no changein humans2OR 1.16
Antithrombotic agents were not clearly linked with cerebral microbleeds in humans (arteriosclerotic cardiovascular diseases).
“In elderly people with risk factors of ASCVD, antithrombotic drug use was not associated with any CMBs, lobar CMBs, or deep CMBs.”
Humansarteriosclerotic cardiovascular diseasesn = 755
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Antithrombotic agents were not clearly linked with cerebral microbleeds in humans (arteriosclerotic cardiovascular diseases) (OR 1.16, 95% CI 0.79–1.71).
“Antithrombotic drug use was not associated with CMB (OR 1.16, 95% CI 0.79–1.71, p = 0.457)”
Humansarteriosclerotic cardiovascular diseasesn = 755
Research SquarePreprint
Intracranial hemorrhage
no changein humans1
1 study
Intracranial hemorrhage
no changein humans1
Antithrombotic agents were not clearly linked with intracranial hemorrhage in humans (older trauma patients) (74% vs. 71%, p = 0.85).
“more intracranial hemorrhages (74% vs. 71%, p = 0.85)”
Humansolder trauma patientsn = 1,112
Short-term impact of preinjury antithrombotic therapy on outcomes in older trauma patients
European journal of trauma and emergency surgery : official publication of the European Trauma Society
Poor functional outcome
no changein humans1OR 1.06
1 study
Poor functional outcome
no changein humans1OR 1.06
Antithrombotic agents were not clearly linked with poor functional outcome in humans (older trauma patients) (OR 1.06, 95% CI 0.79–1.43).
“or poor GOS at discharge (OR, 1.06; 95% CI, 0.79–1.43).”
Humansolder trauma patientsn = 1,112
Short-term impact of preinjury antithrombotic therapy on outcomes in older trauma patients
European journal of trauma and emergency surgery : official publication of the European Trauma Society
In-hospital mortality
no changein humans1OR 0.79
1 study
In-hospital mortality
no changein humans1OR 0.79
Antithrombotic agents were not clearly linked with in-hospital mortality in humans (older trauma patients) (adjusted OR 0.79, 95% CI 0.41–1.53).
“PAM was not associated with higher ISS (median 9 in both groups, p = 0.80), more intracranial hemorrhages (74% vs. 71%, p = 0.85), increased mortality (adjusted odds ratio [OR], 0.79; 95% Confidence Interval [CI], 0.41–1.53)”
Humansolder trauma patientsn = 1,112
Short-term impact of preinjury antithrombotic therapy on outcomes in older trauma patients
European journal of trauma and emergency surgery : official publication of the European Trauma Society
Recurrence requiring reoperation
no changein humans1
1 study
Recurrence requiring reoperation
no changein humans1
Antithrombotic agents were not clearly linked with recurrence requiring reoperation in humans after surgical treatment of nonacute subdural hematoma.
“Preoperative use of antithrombotic agents was not significantly associated with increased recurrence requiring reoperation.”
Humansafter surgical treatment of nonacute subdural hematoma
Cureus
Bone fracture
no changein humans1
1 study
Bone fracture
no changein humans1
Antithrombotic agents were not clearly linked with bone fracture in humans after ground-level falls (23.9%).
“At least one fracture was diagnosed for 23.9% of the population, mostly hip fractures, without any significant association with AT.”
Humansafter ground-level fallsn = 1,014
Ground-level falls among nonagenarians: the impact of pre-injury antithrombotic therapy
Internal and emergency medicine
What is antithrombotic agents linked with?
7Studies link antithrombotic agents with 7 measures, among them early-onset dementia, age-related macular degeneration and lung cancer.
Early-onset dementia
upin humans1OR 1.57
1 study
Early-onset dementia
upin humans1OR 1.57
Antithrombotic agents are linked with a higher risk of early-onset dementia in humans (population-based matched case-control) (OR 1.57, 95% CI 1.06-2.33).
“antithrombotics (OR = 1.57, 95% CI 1.06-2.33), and in individuals <55 years for most antihypertensive classes.”
Humanspopulation-based matched case-controlmales
Nutrition, metabolism, and cardiovascular diseases : NMCD
Age-related macular degeneration
upin humans1HR 1.145
1 study
Age-related macular degeneration
upin humans1HR 1.145
Antithrombotic agents are linked with a higher risk of age-related macular degeneration in humans (HR 1.145, p = 0.042).
“antithrombotic (HR 1.145, p = 0.042) medication”
Humans≥5 yearsfemalesn = 16,518
The impact of systemic long-term medications for the development of age-related macular degeneration
Acta ophthalmologica
Lung cancer
downin humans1
1 study
Lung cancer
downin humans1
Antithrombotic agents are linked with a lower risk of lung cancer in humans.
“after outlier correction, the suggestive association for antithrombotic agents became statistically significant”
Humans
Risk insights for clinical medication: a Mendelian randomization study of 23 drugs and lung cancer
Naunyn-Schmiedeberg's archives of pharmacology
Dementia with Lewy bodies
upin humans1OR 2.12
1 study
Dementia with Lewy bodies
upin humans1OR 2.12
Antithrombotic agents are linked with a higher risk of dementia with Lewy bodies in humans (two-sample Mendelian randomization, inverse-variance weighted estimate) (OR 2.12, 95% CI 1.03-4.34, p = 0.04).
“antithrombotic agents (odds ratio [OR] = 2.12, 95% confidence interval [CI] = 1.03-4.34, p = 0.04)”
Humanstwo-sample Mendelian randomization, inverse-variance weighted estimate
Brain and behavior
Gross hematuria
upin humans1
1 study
Gross hematuria
upin humans1
Antithrombotic agents are linked with a higher risk of gross hematuria in humans (nonagenarians admitted to a urological ward) (aRR = 1.40, 95% CI 1.02-1.92, p = 0.013).
“Antithrombotic therapy (aRR = 1.40, 95% CI 1.02-1.92, p = 0.013) and history of bladder cancer (aRR = 1.46, 95% CI 1.08-1.96, p = 0.013) were significantly associated with hematuria-related admissions.”
Humansnonagenarians admitted to a urological ward
Gross hematuria in nonagenarians admitted to a urological ward: prevalence, predictors, and outcomes
World journal of urology
Intracranial hemorrhage
upin humans1
1 study
Intracranial hemorrhage
upin humans1
Antithrombotic agents are linked with a higher risk of intracranial hemorrhage in humans after ground-level falls (p < 0.015).
“Intracranial hemorrhage (ICH, n = 43, 4.2%), mostly subdural hematomas (58%), were more frequently found among patients with AT (p < 0.015).”
Humansafter ground-level fallsn = 1,014
Ground-level falls among nonagenarians: the impact of pre-injury antithrombotic therapy
Internal and emergency medicine
Head trauma
upin humans1
1 study
Head trauma
upin humans1
Antithrombotic agents are linked with a higher risk of head trauma in humans after ground-level falls (49.2 vs 28.6%, p < 0.001).
“Head trauma (n = 429, 42.3%) was significantly more frequent among patients with AT (49.2 vs 28.6%, p < 0.001).”
Humansafter ground-level fallsn = 1,014
Ground-level falls among nonagenarians: the impact of pre-injury antithrombotic therapy
Internal and emergency medicine